{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:41:08Z","timestamp":1788518468774,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Trials typically group cancers of the gastro-oesophageal junction (GOJ) with oesophageal or gastric cancer when studying neoadjuvant chemoradiation and perioperative chemotherapy, so the results may not be fully applicable to GOJ cancer. Because optimal neoadjuvant treatment for GOJ cancer remains controversial, outcomes with neoadjuvant chemoradiation versus chemotherapy for locally advanced GOJ adenocarcinoma were compared retrospectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were collected from all patients who underwent neoadjuvant treatment followed by surgery for adenocarcinoma located at the GOJ at a single high-volume institution between 2002 and 2017. Postoperative major complications and mortality were compared between groups using Fisher\u2019s exact test. Overall survival (OS) and disease-free survival (DFS) were assessed by log rank test and multivariable Cox regression analyses. Cumulative incidence functions were used to estimate recurrence, and groups were compared using Gray\u2019s test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 775 patients, 650 had neoadjuvant chemoradiation and 125 had chemotherapy. These groups were comparable in terms of clinical tumour and lymph node categories, although the chemoradiation group had greater proportions of white men, complete pathological response to chemotherapy, and smaller proportions of diffuse cancer, poor differentiation, and neurovascular invasion. Postoperative major complications (20.0 versus 17.6 per cent) and 30-day mortality (1.7 versus 1.6 per cent) were not significantly different between the chemoradiation and chemotherapy groups. After adjustment, type of therapy (chemoradiation versus chemotherapy) was not significantly associated with OS (hazard ratio (HR) 1.26, 95 per cent c.i. 0.96 to 1.67) or DFS (HR 1.27, 0.98 to 1.64). Type of recurrence (local, regional, or distant) did not differ after neoadjuvant chemoradiation versus chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients undergoing surgical resection for locally advanced adenocarcinoma of the GOJ, OS and DFS did not differ significantly between patients who had neoadjuvant chemoradiation compared with chemotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjs\/znab228","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T19:42:12Z","timestamp":1622230932000},"page":"1332-1340","source":"Crossref","is-referenced-by-count":12,"title":["Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma"],"prefix":"10.1093","volume":"108","author":[{"given":"E L","family":"Vos","sequence":"first","affiliation":[{"name":"Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Carr","sequence":"additional","affiliation":[{"name":"Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nakauchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Nobel","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mount Sinai Health System , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Massachusetts Medical School , Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Barbetta","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Southern California , Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K S","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Experimental and Gastrointestinal Pathology Services, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Ilson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Y","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y Y","family":"Janjigian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5006-4454","authenticated-orcid":false,"given":"S S","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Bains","sequence":"additional","affiliation":[{"name":"Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D R","family":"Jones","sequence":"additional","affiliation":[{"name":"Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Coit","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Molena","sequence":"additional","affiliation":[{"name":"Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V E","family":"Strong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"2023101411232186400_znab228-B1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2023101411232186400_znab228-B2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/SLA.0000000000001905","article-title":"Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis","volume":"265","author":"Pasquali","year":"2017","journal-title":"Ann Surg"},{"key":"2023101411232186400_znab228-B3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"2023101411232186400_znab228-B4","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023101411232186400_znab228-B5","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.3390\/jcm9113495","article-title":"Treatment patterns for gastroesophageal junction adenocarcinoma in the United States","volume":"9","author":"Kim","year":"2020","journal-title":"J Clin Med"},{"key":"2023101411232186400_znab228-B6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10120-018-0901-3","article-title":"Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis","volume":"22","author":"Petrelli","year":"2019","journal-title":"Gastric Cancer"},{"key":"2023101411232186400_znab228-B7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/annonc\/mdw560","article-title":"Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study","volume":"28","author":"Markar","year":"2017","journal-title":"Ann Oncol"},{"key":"2023101411232186400_znab228-B8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10120-019-00980-6","article-title":"Survival after neoadjuvant approaches to gastroesophageal junction cancer","volume":"23","author":"Xiang","year":"2020","journal-title":"Gastric Cancer"},{"key":"2023101411232186400_znab228-B9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.athoracsur.2020.03.024","article-title":"Preoperative chemoradiation versus chemotherapy in gastroesophageal junction adenocarcinoma","volume":"110","author":"Zafar","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"2023101411232186400_znab228-B10","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.athoracsur.2015.11.070","article-title":"Preoperative chemoradiation therapy versus chemotherapy in patients undergoing modified en bloc esophagectomy for locally advanced esophageal adenocarcinoma: is radiotherapy beneficial?","volume":"101","author":"Spicer","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"2023101411232186400_znab228-B11","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/bjs.10304","article-title":"Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry","volume":"103","author":"Klevebro","year":"2016","journal-title":"Br J Surg"},{"key":"2023101411232186400_znab228-B12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","article-title":"Classification of adenocarcinoma of the oesophagogastric junction","volume":"85","author":"Siewert","year":"1998","journal-title":"Br J Surg"},{"key":"2023101411232186400_znab228-B13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"2023101411232186400_znab228-B14","article-title":"Comprehensive molecular characterization of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas","author":"Suh","year":"2020","journal-title":"Ann Surg"},{"key":"2023101411232186400_znab228-B15","volume-title":"AJCC Cancer Staging Manual","author":"Amin","edition":"8th edn"},{"key":"2023101411232186400_znab228-B16","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric cancer, version 3.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"2023101411232186400_znab228-B17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"2023101411232186400_znab228-B18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1245\/s10434-014-4141-4","article-title":"Development and assessment of Memorial Sloan Kettering Cancer Center\u2019s Surgical Secondary Events grading system","volume":"22","author":"Strong","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2023101411232186400_znab228-B19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/dote.12082","article-title":"Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma","volume":"27","author":"Gerber","year":"2014","journal-title":"Dis Esophagus"},{"key":"2023101411232186400_znab228-B20","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"2023101411232186400_znab228-B21","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2018.36.15_suppl.4012","article-title":"Survival outcomes from CALGB 80803 (Alliance): a randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer","volume":"36","author":"Goodman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023101411232186400_znab228-B22","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"2023101411232186400_znab228-B23","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023101411232186400_znab228-B24","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJM199812313392704","article-title":"Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer","volume":"339","author":"Kelsen","year":"1998","journal-title":"N Engl J Med"},{"key":"2023101411232186400_znab228-B25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction","volume":"27","author":"Stahl","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023101411232186400_znab228-B26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/annonc\/mdw010","article-title":"A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction","volume":"27","author":"Klevebro","year":"2016","journal-title":"Ann Oncol"},{"key":"2023101411232186400_znab228-B27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ejca.2010.09.009","article-title":"Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial","volume":"47","author":"Burmeister","year":"2011","journal-title":"Eur J Cancer"},{"key":"2023101411232186400_znab228-B28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12885-018-4770-2","article-title":"CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer","volume":"18","author":"Slagter","year":"2018","journal-title":"BMC Cancer"},{"key":"2023101411232186400_znab228-B29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12885-017-3386-2","article-title":"ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)","volume":"17","author":"Reynolds","year":"2017","journal-title":"BMC Cancer"},{"key":"2023101411232186400_znab228-B30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s12885-015-1529-x","article-title":"TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG\/TROG\/EORTC\/NCIC CTG)","volume":"15","author":"Leong","year":"2015","journal-title":"BMC Cancer"},{"key":"2023101411232186400_znab228-B31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","article-title":"ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)","volume":"16","author":"Hoeppner","year":"2016","journal-title":"BMC Cancer"},{"key":"2023101411232186400_znab228-B32","doi-asserted-by":"crossref","DOI":"10.1093\/dote\/doy078","article-title":"Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial","volume":"32","author":"von Dobeln","year":"2019","journal-title":"Dis Esophagus"},{"key":"2023101411232186400_znab228-B33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ags3.12268","article-title":"Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma","volume":"3","author":"Nobel","year":"2019","journal-title":"Ann Gastroenterol Surg"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/108\/11\/1332\/52137388\/znab228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/108\/11\/1332\/52137388\/znab228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:23:52Z","timestamp":1697282632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/108\/11\/1332\/6363085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,9,3]]},"published-print":{"date-parts":[[2021,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znab228","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,9,3]]}}}